Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of [14C] Pacritinib in Healthy Male Subjects
NCT02803762Phase 1Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Jul 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pacritinib in myelofibrosis (MF), sponsored by CTI BioPharma Corp. Primary endpoints: Maximum Plasma Concentration at 168 hours, Time to Maximum Plasma Concentration at 168 hours and 3 more. Started Jul 2014; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02803762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02803762.